Performance of everolimus-eluting and paclitaxel-eluting coronary stents in women: 2-year outcomes from the SPIRIT IV trial




Background


Women with coronary artery disease are at higher risk for adverse outcomes than men after coronary intervention. The SPIRIT IV clinical trial, a prospective, multicenter, randomized controlled trial, compared treatment with the XIENCE V® (Abbott Vascular, Santa Clara, CA, USA) everolimus-eluting stent (EES) to the TAXUS® (Boston Scientific, Natick, MA, USA) paclitaxel-eluting stent (PES), demonstrating similar reductions in TLF, MACE and stent thrombosis in women and in men at 1 year. Clinical outcomes in patients treated with EES were generalizable across genders at 1 year. Outcomes at 2 years have not been reported.




Methods


The SPIRIT IV clinical trial enrolled 3687 subjects at 66 US institutions; 32.2% ( n =1188) were women. All patients underwent PCI of up to three native de novo coronary artery lesions ≤28 mm in length with reference vessel diameters between 2.5 and 4.25 mm.

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Coronary stenting with MGuard: extended follow-up of first human trial
  2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
  3. Treatment of STEMI with neither PCI nor thrombolysis
  4. Definite stent thrombosis: a 2-center New Zealand registry

Stay updated, free articles. Join our Telegram channel
Tags:
Nov 16, 2017 | Posted by in CARDIOLOGY | Comments Off on Performance of everolimus-eluting and paclitaxel-eluting coronary stents in women: 2-year outcomes from the SPIRIT IV trial

Full access? Get Clinical Tree
Get Clinical Tree app for offline access